The Women's Health Initiative Estrogen-alone Trial had differential disease and medical expenditure consequences across age groups.

ABSTRACT:

Objectives

The Women's Health Initiative (WHI) randomized trial identified age differences in the benefit-risk profile of estrogen-alone (ET) use. The impact of WHI trial on disease-associated medical expenditures attributable to subsequent decreased ET utilization has, however, not been measured. Therefore, the objective of this analysis was to quantify the age-specific disease-associated medical expenditures attributable to reduced ET utilization after the WHI Hormone Therapy (HT) trials.

Methods

Population-level disease counts and associated expenditures between 2003 and 2015 were compared between an observed ET-user population versus a hypothetical ET-user population assuming absence of the WHI HT trials, constructed by extrapolating ET utilization rates from 1996 to 200

SUBMITTER: Donneyong MM 

PROVIDER: S-EPMC7255959 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature